ETS1 (Gene)

Synonyms:ENTREZ:2113, ETS proto-oncogene 1, transcription factor, ETS-1, ETS1, EWSR2, HGNC:3488, MIM:164720, NM_001143820, NM_001162422, NM_001330451, NM_005238, NP_001137292, NP_001155894, NP_001317380, NP_005229, XM_011542650, XM_017017314, XM_017017315, XM_017017317, XP_011540952, XP_016872803, XP_016872804, XP_016872806, c-ets-1, p54
Omim:OMIM:164720
Id:ENSG00000134954
Hgnc:HGNC:3488
Entrez:2113
Description:ETS proto-oncogene 1, transcription factor
This gene encodes a member of the ETS family of transcription factors, which are defined by the presence of a conserved ETS DNA-binding domain that recognizes the core consensus DNA sequence GGAA/T in target genes. These proteins function either as transcriptional activators or repressors of numerous genes, and are involved in stem cell development, cell senescence and death, and tumorigenesis. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.[provided by RefSeq, Jul 2011]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ETS1's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ETS1.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ETS1.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ETS1.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ETS1.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.